Search for European Projects

10 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Parasite-specific cyclic nucleotide phosphodiesterase inhibitors to target Neglected Parasitic Diseases (PDE4NPD)

Start date: Mar 1, 2014, End date: Feb 28, 2018,

This project aims to unite global efforts to target the highly druggable class of enzymes called cyclic nucleotide phosphodiesterases (PDEs) in the fight for neglected parasitic diseases (NPD). It will establish a drug discovery platform, PDE4NPD, that combines phenotypic screening with efficient target-centric drug discovery, including target validation, various strategies for compound screening, ...
Read Project

 11

 FINISHED 

Molecular basis of the outer membrane permeability (TRANSLOCATION)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and development of new antibiotics. To respond to this Call we are extending our current network on antibiotic translocation and propose an ambitious project ranging from identification of novel resistance mechanisms in clinical bacterial isolates to crystallizat ...
Read Project

 28

 FINISHED 

Kinetics for Drug Discovery (K4DD) (K4DD)

Start date: Nov 1, 2012, End date: Oct 31, 2017,

...inity and selectivity. For us, integration means analyzing the kinetic behavior of different targets (GPCRs, kinases, proteases) across the three work packages. The partners in the consortium are European key players: they elucidate(d) structures of GPCRs and kinases, are at the forefront of bioanalytical techniques, e.g. surface plasmon resonance, are world-leaders in PKPD modeling, and bring the ...
Read Project

 21

 FINISHED 

MOLECULAR BASIS OF ANTIBIOTIC TRANSLOCATION (Translocation)

Start date: Sep 1, 2013, End date: Aug 31, 2017,

Multidrug resistant bacteria are now ubiquitous in both hospitals and the larger community. Drug-resistant pathogens are becoming increasingly pervasive, for example, the resurrection of tuberculosis provides one ominous example highlighting the risk associated with evolved drug resistance. Moreover, many pharmaceutical companies abandoned this field and no truly novel active antibacterial compoun ...
Read Project

 11

 FINISHED 

Chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population (EURHYTHDIA)

Start date: Oct 1, 2011, End date: Jun 30, 2017,

...ght disturb the circadian clocks and severely disrupt endocrine and metabolic processes, contributing to an increased risk of type 2 diabetes/obesity. Especially shift workers constituting 20% of the European working population are affected by this prob-lem. Until now only few studies investigating circadian rhythm disturbances in the context of type 2 diabetes/obesity have been conducted in man. ...
Read Project

 17

 FINISHED 

Exploitation of genomic variants affecting coronary artery disease and stroke risk for therapeutic intervention (CVGENES-AT-TARGET)

Start date: Oct 1, 2013, End date: Mar 31, 2017,

Atherosclerosis and its most disabling sequelae, coronary artery disease (CAD) and stroke, are leading causes of death in Europe. Until now, preventive and therapeutic interventions for these diseases aim at ameliorating the effects of established cardiovascular risk factors. More recently, results of genome-wide association (GWA) studies added to our perception of mechanisms leading to atheroscle ...
Read Project

 13

 FINISHED 

New Medicines for Trypanosomatidic Infections (NMTRYPI)

Start date: Feb 1, 2014, End date: Jan 31, 2017,

The infectious diseases burden imposed by the parasites of Trypanosomatidae family represents a huge problem on people’s lives in countries where these diseases are endemic. Problems associated with existing drugs include inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. New drugs are urgently needed now and in the foreseeable future. The New Medicine for T ...
Read Project

 14

 FINISHED 

Hanging Drop based automated and parallelized cell technology platform for production and testing (DropTech)

Start date: Feb 1, 2014, End date: Jan 31, 2017,

Cell-based screenings are today a necessary tool for all types of clinical development and/or market approval of new drugs and chemicals. The major change in the last decade is a shift towards more physiologically relevant yet complex and sensitive cell models, like stem cells, and more recently, the shift to human induced pluripotent cells. Stem-cell technology has the potential to revolutionize ...
Read Project

 4

 FINISHED 

European Bank for induced pluripotent Stem Cells (EBISC)

Start date: Jan 1, 2014, End date: Dec 31, 2016,

...g and regenerative medicine, and scholars in law and ethics. The main facility will be at the Babraham Research Campus (Cambridge, UK) and will undertake cell expansion, QC and characterisation. The European Cell Culture Collection (ECACC) of Public Health England (Department of Health, UK) will coordinate cell line distribution. The Fraunhofer IBMT (Saarbrücken, Germany) will provide comprehensi ...
Read Project

 30

 FINISHED 

Natural products from marine fungi for the treatment of cancer (MARINE FUNGI)

Start date: May 1, 2011, End date: Apr 30, 2014,

The aim of MARINE FUNGI is the demonstration of sustainable exploitation of marine natural resources providing appropriate culture conditions for the underutilised group of marine fungi, thus enabling efficient production of marine natural products in the laboratory and also in large scale cultures, avoiding harm to the natural environment. The focus of MARINE FUNGI are new anti-cancer compounds T ...
Read Project

 14